Associated Papers
Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.
Page K et al.
Breast Cancer Research and Treatment, 2025
41364261 (PubMed )
Supplement: 10549_2025_7857_MOESM7_ESM.xlsx › Supp_Table_5
Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients.
Borkar S et al.
Cancers, 2025
40282442 (PubMed )
Supplement: cancers-17-01266-s001.zip › cancers-3540268-supplementary.pdf
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.
Boscolo Bielo L et al.
Esmo Open, 2024
Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation.
Irani S et al.
The Journal of Clinical Investigation, 2024
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
Pascual J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
37490393 (PubMed )
Supplement: ccr-23-0956_supplementary_table_s2_suppts2.xlsx › PEARL_baseline_mutations
Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice.
Bruzas S et al.
Cancers, 2021
34572791 (PubMed )
Supplement: cancers-13-04564-s001.zip › cancers-1336427-supplementary › Supplementary_material › Table_S1_-_Genetic_alterations_identified_by_NGS_in_95_patients_with_metastatic_breast_cancer.xlsx › Table_S1
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.
Razavi P et al.
Nature Cancer, 2020
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
Toy W et al.
Cancer Discovery, 2017
Select a paper to view details